跳至主要内容
临床试验/ACTRN12624000462583
ACTRN12624000462583
招募中
未知

FAST study: Feasibility ASessment of circulating Tumour DNA (ctDNA) in the diagnosis of advanced lung cancer in patients

niversity of Otago0 个研究点目标入组 50 人2024年4月15日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
ung cancer
发起方
niversity of Otago
入组人数
50
状态
招募中
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2024年4月15日
结束日期
待定
最后更新
去年
研究类型
Interventional
性别
All

研究者

入排标准

入选标准

  • 1\.Participant is willing and able to give informed consent for participation in the trial.
  • 2\.Male or female, aged 18 years or above.
  • 3\.Radiological advanced lung cancer (distant metastases as per American Joint Committee on Cancer (AJCC) 8th edition Tumour, Nodes, Metastasis (TNM) staging, stage M1a, M1b or M1c)
  • 4\.Radiologist confirmed suspicion of malignancy on chest X\-Ray (CXR) or computerised tomography (CT) and clinician opinion likely lung cancer primary
  • 5\.Not suitable for cytotoxic chemotherapy but fit for molecularly targeted treatment, due to patient comorbidity, performance status or patient preference
  • 6\.Unable to pursue molecular testing of a histological sample
  • a.Due to anatomical location/risk of complications or,
  • b.Due to patient preference or,
  • c.Due to insufficient material for molecular testing
  • 7\.Life expectancy expected more than 4 weeks

排除标准

  • European Cooperative Oncology Group Performance status (ECOG PS) 4
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.

结局指标

主要结局

未指定

相似试验